Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey

Oral anticoagulation (OAC) is superior to antiplatelet therapy to prevent stroke in patients with atrial fibrillation (AF). In contrast, patients who have experienced an acute coronary event and/or coronary stent placement benefit from antiplatelet therapy to prevent future adverse cardiac events. While both of these cardiac conditions are highly prevalent on their own, they also frequently occur concurrently. In these situations, combined antiplatelet therapy and OAC significantly increases the risk of bleeding events [1,2].

Source: Thrombosis Research - May 26, 2019 Category: Hematology Authors: David Kopin, W. Schuyler Jones, Andrew Klein, Geoffrey D. Barnes Tags: Letter to the Editors-in-Chief Source Type: research